PT1955700E - Tratamento terap?utico de doen?as associadas ao receptor de androg?nios - Google Patents

Tratamento terap?utico de doen?as associadas ao receptor de androg?nios Download PDF

Info

Publication number
PT1955700E
PT1955700E PT08003806T PT08003806T PT1955700E PT 1955700 E PT1955700 E PT 1955700E PT 08003806 T PT08003806 T PT 08003806T PT 08003806 T PT08003806 T PT 08003806T PT 1955700 E PT1955700 E PT 1955700E
Authority
PT
Portugal
Prior art keywords
androgen receptor
therapeutic treatment
driven conditions
receptor driven
conditions
Prior art date
Application number
PT08003806T
Other languages
English (en)
Inventor
James M Frincke
Original Assignee
Harbor Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Biosciences Inc filed Critical Harbor Biosciences Inc
Publication of PT1955700E publication Critical patent/PT1955700E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
PT08003806T 1999-09-30 2000-09-28 Tratamento terap?utico de doen?as associadas ao receptor de androg?nios PT1955700E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15727599P 1999-09-30 1999-09-30
US15734799P 1999-09-30 1999-09-30
US16611699P 1999-11-16 1999-11-16

Publications (1)

Publication Number Publication Date
PT1955700E true PT1955700E (pt) 2011-05-04

Family

ID=27387982

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08003806T PT1955700E (pt) 1999-09-30 2000-09-28 Tratamento terap?utico de doen?as associadas ao receptor de androg?nios

Country Status (9)

Country Link
US (7) US7696189B1 (pt)
EP (4) EP1228083A2 (pt)
AT (1) ATE501722T1 (pt)
AU (1) AU7736300A (pt)
CA (3) CA2386095A1 (pt)
DE (1) DE60045751D1 (pt)
DK (1) DK1955700T3 (pt)
PT (1) PT1955700E (pt)
WO (1) WO2001023405A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
AU2001241779A1 (en) * 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
CA2497838C (en) * 2002-09-05 2012-07-17 Pantarhei Bioscience B.V. Pharmaceutical application of 15- or 16- substituted testosterone analogues
EP1615944A4 (en) 2003-04-01 2010-08-11 Harbor Biosciences Inc ANTI-ORANGE PROBLEMS WITH MARGINAL AGONIST EFFECT AND METHOD OF USE
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
WO2006110172A2 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals.Inc. Steroid analogs and characterization and treatment methods
US20060073099A1 (en) * 2004-10-01 2006-04-06 Frincke James M Treatment screening methods
CA2649940C (en) * 2006-04-22 2012-08-07 Hollis-Eden Pharmaceuticals, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
EP1854465A1 (en) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
US8460240B2 (en) * 2006-08-07 2013-06-11 W. L. Gore & Associates, Inc. Inflatable toroidal-shaped balloons
US20080125711A1 (en) * 2006-08-07 2008-05-29 Alpini Alfred A Catheter balloons with integrated non-distensible seals
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
US20080153792A1 (en) * 2006-11-17 2008-06-26 Frincke James M Drug Identification and Treatment Method
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
DK2060300T3 (da) * 2007-11-13 2015-06-22 Curadis Gmbh C-19-steroider til terapeutiske anvendelser
JP2011511011A (ja) * 2008-02-05 2011-04-07 ハーバー バイオサイエンシーズ，インコーポレイテッド 医薬的固体状態形態
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
PT2273994E (pt) 2008-04-03 2016-03-15 Neurmedix Inc Formas de estado sólido de um produto farmacêutico
US8309746B2 (en) 2008-06-06 2012-11-13 Harbor Therapeutics, Inc Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
US20100227841A1 (en) * 2008-09-24 2010-09-09 Harbor BioSciencs, Inc. Patient populations and treatment methods
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
CA2782266A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
SG11201507093WA (en) * 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
TN2016000240A1 (en) 2013-12-24 2017-10-06 Harvard College Cortistatin analogues and syntheses and uses thereof.
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2332486A (en) 1935-02-23 1943-10-19 Schering Corp Acyl compounds of polycyclic alcohols with germinal gland hormone characteristics and a method for producing the same
US2308833A (en) 1935-06-18 1943-01-19 Ciba Pharm Prod Inc Polynuclear cyclic oxyketones and derivatives thereof and process of making same
US2243887A (en) 1935-11-09 1941-06-03 Schering Corp Tertiary carbinols of the cyclopentano-polyhydrophenanthrene series and a method of producing the same
US2251939A (en) 1935-11-22 1941-08-12 Schering Corp Tertiary alcohols of the cyclopentano polyhydro phenanthrene series and a method of producing the same
US2308834A (en) 1936-06-15 1943-01-19 Ciba Pharm Prod Inc Polynuclear cyclic oxyketones and derivatives thereof and process of making same
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
US2267258A (en) 1937-08-12 1941-12-23 Ciba Pharm Prod Inc Derivatives of saturated and unsaturated compounds of the cyclopentanopolyhydrophenanthrene series and process of producing same
US2266778A (en) 1937-10-05 1941-12-23 Schering Corp Unsaturated compounds of the cyclopentanopolyhydrophenanthrene series with an unsaturated side chain in the cyclopentano nucleus and a process for their manufacture
US2318105A (en) 1938-07-23 1943-05-04 Ciba Pharm Prod Inc Hydrated acetylene derivatives of the cyclopentanopolyhydrophenanthrene series and process of preparing same
US2357364A (en) 1940-03-22 1944-09-05 Squibb & Sons Inc Keto derviatives of 17-ethynyl-17-hydroxy-perhydrocyclopentenophenanthrenes and process of preparing them
US2713062A (en) 1952-08-08 1955-07-12 Schering Ag 3-methyl-17-ethinyl androstandiols
NL190146A (pt) 1953-08-26
US2830063A (en) 1955-07-21 1958-04-08 Sterling Drug Inc 3beta-cycloalkylacyloxy -17beta-hydroxy-17alpha-ethynyl-5-androstenes and androstanes and their preparation
US2868811A (en) 1955-07-21 1959-01-13 Sterling Drug Inc 3beta-acyloxy-17beta-hydroxy-17alpha-ethynyl-5-androstenes and androstanes and theirpreparation
US2844602A (en) 1956-01-31 1958-07-22 Syntex Sa 4-methyl testosterone compounds
CH366275A (de) 1956-02-07 1962-12-31 Syntex Sa Verfahren zur Herstellung von Steroiden
US3262949A (en) 1956-11-13 1966-07-26 Syntex Corp 7-methyl androstane compounds
US2833793A (en) 1957-09-30 1958-05-06 Searle & Co 17-oxygenated derivatives of 5-androstene-1, 3-diol
US2838500A (en) 1957-11-29 1958-06-10 Upjohn Co 6-fluoro steroids
US2911418A (en) 1959-01-02 1959-11-03 Searle & Co 16-halo 17-oxygenated androst-5-en-3-ols and esters
US3029263A (en) 1959-12-24 1962-04-10 Upjohn Co 7-methyl-4, 6-androstadienes
US3045032A (en) 1960-02-08 1962-07-17 Schering Corp Fluorinated androstanes
US3014935A (en) 1960-06-15 1961-12-26 Searle & Co 5alpha-estrane-3alpha, 17beta-diols and esters thereof
US3148198A (en) 1960-09-06 1964-09-08 Searle & Co 3, 17-bisoxygenated 16alpha, 16beta-difluoroandrostenes and process
US3210249A (en) 1962-02-01 1965-10-05 Merck Ag Fa E Pharmaceutical composition comprising 7-methoxy-17alpha-methyl-testosterone
BE639453A (pt) 1962-06-18
US3187023A (en) 1962-10-18 1965-06-01 Schering Corp 16, 16-difluoro-17alpha-halogenoethinyl androstanes
US3200113A (en) 1963-01-09 1965-08-10 Sterling Drug Inc 7-cyano steroids and derivatives thereof
US3176030A (en) 1963-10-16 1965-03-30 Lasdon Foundation Inc 16alpha-lowerhydrocarbon-androsten-16beta-ol-3-one and 16-alpha-lowerhydrocarbon-androsten-16beta-ol-3-ol compounds
DE1240859B (de) 1963-11-09 1967-05-24 Schering Ag Verfahren zur Herstellung von Androstan-1alpha, 3alpha, 17beta-triol und seinen Estern
GB1093125A (en) 1963-11-28 1967-11-29 Novo Terapeutisk Labor As Improvements in or relating to new and therapeutically active derivatives of 1,2-cyclopentanoperhydrophen-anthrene
US3522243A (en) 1964-03-17 1970-07-28 Sterling Drug Inc Omega-amino 1-alkynyl steroids and reduction products thereof
BE666194A (pt) 1964-06-30
DE1235316B (de) 1964-11-17 1967-03-02 Schering Ag Verfahren zur Herstellung von 17alpha-AEthinyl-delta 1,3,5(10)-oestratrien-3, 16alpha17beta-triol sowie seiner Ester und AEther
US3299107A (en) 1965-02-12 1967-01-17 Searle & Co 17-(unsaturated hydrocarbon-substituted)-3-hydroxyimino-5alpha-androstan-17beta-ols,alkyl and acyl derivatives thereof
US3357888A (en) 1965-04-07 1967-12-12 Upjohn Co 4, 7-dimethyl androstene derivatives
DE1593090A1 (de) 1966-09-26 1970-06-04 Merck Ag E 17 alpha-Cyanaethinylsteroide sowie Verfahren zu ihrer Herstellung
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3654320A (en) 1970-03-24 1972-04-04 Upjohn Co Organic processes
US3711606A (en) 1970-09-02 1973-01-16 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active steroidal agents with dmso
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3869467A (en) 1972-06-05 1975-03-04 Hoffmann La Roche 17-{62 -Hydroxy-17-{60 -methyl-5-{60 -androstano{9 3,2-c{9 or{8 2,3-d{9 isoxazoles
US3962275A (en) 1972-06-05 1976-06-08 Hoffmann-La Roche Inc. 7-oxa steroids
US3734935A (en) 1972-07-21 1973-05-22 American Home Prod Biologically active 17alpha-ethynyl-16,17-dihydroxy-13-alkygonanes
US3944546A (en) * 1972-08-04 1976-03-16 E. R. Squibb & Sons, Inc. Cyanomethylthioacetylcephalosporins
US3976691A (en) 1972-12-11 1976-08-24 E. I. Du Pont De Nemours And Company Dialkylaminosulfur trifluorides as fluorinating agents
NL7305171A (pt) 1973-04-13 1974-10-15
DK290774A (pt) 1973-06-08 1975-02-03 Schering Ag
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
YU243975A (en) 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US4059630A (en) 1976-02-26 1977-11-22 The Johns Hopkins University Anti-androgenic steroids
GB1523965A (en) 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE2705917C3 (de) 1977-02-09 1980-05-08 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 3 ß , 16 ß -Dihydroxy-5-androsten- 17-on durch mikrobiologische Hydrolyse
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4268441A (en) 1979-03-13 1981-05-19 Interx Research Corporation Prodrugs for improved bioavailability of certain Δ4 -3-ketosteroidal sex hormones
NZ193564A (en) 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
DE2943776A1 (de) 1979-10-26 1981-05-14 Schering Ag Berlin Und Bergkamen, 1000 Berlin 17 (alpha) -alkylsteroide, diese enthaltende praeparate sowie verfahren zu ihrer herstellung
US4542129A (en) 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
US5714481A (en) 1983-08-02 1998-02-03 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17 ones and 5-androstan-17-ones
US5804576A (en) 1983-08-02 1998-09-08 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17-ones and 5-androstan-17-ones
EP0423842A3 (en) 1983-08-02 1991-08-07 Research Corporation Steroids and therapeutic compositions containing same
US5656621A (en) 1983-08-02 1997-08-12 Research Corporation Tech., Inc. Steroids useful as anti-cancer and anti-obesity agents
US5157031A (en) 1983-08-02 1992-10-20 Research Corporation Technologies, Inc. Method for prophylaxis of obesity
US4666898A (en) 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
SE8403905D0 (sv) 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4602008A (en) 1984-12-14 1986-07-22 Progenics, Inc. Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent
JPS62175497A (ja) 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd 胆汁酸誘導体およびその製造法
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
NL194728C (nl) 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US5075464A (en) * 1987-04-22 1991-12-24 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropylamino)androstene derivatives
US5028631A (en) 1987-11-25 1991-07-02 Schwartz Arthur G Homoandrostan-17-one and homoandrosten-17-ones
US5175154A (en) 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
US5001119A (en) 1987-11-25 1991-03-19 Schwartz Arthur G 16-substituted androstanes and 16-substituted androstenes
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US4989694A (en) 1988-03-09 1991-02-05 Hitachi, Ltd. Elevator group supervisory system
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US5208263A (en) * 1988-09-30 1993-05-04 Arch Development Corporation Anti-androgen compounds
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5077284A (en) 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
US5461042A (en) 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
US5407684A (en) 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5372996A (en) 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
DE3918543A1 (de) 1989-06-07 1990-12-13 Boehringer Mannheim Gmbh Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
KR0181264B1 (ko) 1989-07-07 1999-03-20 라브리 페르낭 성스테로이드 활성 억제용 안드로겐 유도체
DK0595796T3 (da) 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US4970204A (en) 1989-08-23 1990-11-13 Smithkline Beecham Corporation 3-substituted nitro-steroid derivatives as 5-α-reductase inhibitors
DE69033541D1 (de) 1989-09-25 2000-06-15 Univ Utah Res Found Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung
US5824313A (en) 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5518725A (en) 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5562910A (en) 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5837269A (en) 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5919465A (en) 1989-09-25 1999-07-06 University Of Utah Research Foundation Methods for augmenting immunological responses through the administration of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S)
DE3938296A1 (de) 1989-11-17 1991-05-23 Waldinger Maschinenbau Gmbh Verfahren und vorrichtung zum verpacken langgestreckter packungen wie arzneimittelampullen in verpackungshuellen
US5641768A (en) 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
CA2028759A1 (en) 1989-11-22 1991-05-23 Jean-Marie Cassal Steroids
SE465524B (sv) * 1990-02-08 1991-09-23 Asea Brown Boveri Anordning foer oeverlast- och kortslutningsskydd i elektriska anlaeggningar
US5137882A (en) 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5807848A (en) 1990-08-29 1998-09-15 Humanetics Corporation Use of dehydroepeiandrosterone-3-carboxylates to control body weight
US5585371A (en) 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
WO1992003925A1 (en) 1990-08-29 1992-03-19 Humanetics Corporation Treatment process for promoting weight loss employing a substituted δ5-androstene
US5641766A (en) 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
US5506223A (en) 1990-08-29 1996-04-09 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5292730A (en) 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5681964A (en) 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5925774A (en) 1991-01-07 1999-07-20 Pherin Corporation Estrenes for inducing hypothalamic effects
US5162198A (en) 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
US5110810A (en) 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
US5206008A (en) 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5338837A (en) 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
CA2117532C (en) 1992-02-24 2001-04-10 Jonathan W. Nyce Method of inhibiting carcinogenesis by treatment with dehydropiandrosterone and analogs thereof
DE69333289T2 (de) 1992-04-01 2004-08-26 The Johns Hopkins University School Of Medicine Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5922701A (en) 1992-05-01 1999-07-13 University Of Utah Research Foundation Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue
US5686438A (en) 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5237064A (en) 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
AU680818B2 (en) 1992-05-21 1997-08-14 Endorecherche Inc. Improved antiandrogens
UA35589C2 (uk) 1992-05-21 2001-04-16 Андорешерш Інк. ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
JPH0653542A (ja) 1992-07-30 1994-02-25 Eastman Kodak Japan Kk 発光ダイオードアレイ
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5561124A (en) 1992-11-18 1996-10-01 Webb; Robert L. 17-α-acyl steroids which inhibit 5-α-reductase
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
AU5855794A (en) 1993-01-19 1994-08-15 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US5977095A (en) 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
US5587369A (en) 1993-03-09 1996-12-24 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5811418A (en) 1993-03-09 1998-09-22 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5635496A (en) 1993-03-09 1997-06-03 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
HUT72968A (en) 1993-03-09 1996-06-28 Univ Utah Res Found Process for producing pharmaceutical composition which is applicable for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5922703A (en) 1993-09-24 1999-07-13 The Procter & Gamble Company Urethane-containing aminosteroid compounds
CA2172497A1 (en) 1993-09-24 1995-03-30 Song Liu Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds
US5478566A (en) 1993-09-29 1995-12-26 Loria; Roger M. Stimulation of cytokine production
EP0721956B1 (en) 1993-09-29 2000-08-02 Nissin Shokuhin Kabushiki Kaisha 21-substituted steroid compound
JP3862295B2 (ja) 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
WO1995010527A1 (en) 1993-10-13 1995-04-20 Neurocrine Biosciences, Inc. 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
US5677336A (en) 1993-10-21 1997-10-14 Ligand Pharmaceuticals Incorporated Non-steroid androgen receptor antagonist compounds and methods
US5424563A (en) * 1993-12-27 1995-06-13 Harris Corporation Apparatus and method for increasing breakdown voltage ruggedness in semiconductor devices
EP0738275B9 (en) 1994-01-06 2001-03-21 Sri International Novel antiandrogenic agents and related pharmaceutical compositions and methods of use
US5527788A (en) 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5567830A (en) 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
KR100338287B1 (ko) 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
US5574022A (en) 1994-04-14 1996-11-12 The Center For Innovative Technology Method of attenuating physical damage to the spinal cord
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5523346A (en) 1994-06-10 1996-06-04 W. L. Gore & Associates, Inc. Seeded microemulsion polymerization for the production of small polymer particles
US5665756A (en) 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US5792757A (en) 1994-08-04 1998-08-11 Pherin Pharmaceuticals 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function
US5776921A (en) 1994-10-20 1998-07-07 Gates; Stephen Compositions for regulation of immune responses
US5559107A (en) 1994-10-20 1996-09-24 Gates; Stephen Regulation of immune response
US6696459B1 (en) 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
US5696127A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5656613A (en) 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
US5886005A (en) 1995-01-17 1999-03-23 Merck & Co., Inc. 4-Aza-19-norandrostane derivatives
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US5856340A (en) 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6150336A (en) 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
PL185523B1 (pl) 1995-06-06 2003-05-30 Cocensys Inc Neuroaktywne steroidy z grupy pochodnych androstanu i pregnanu oraz kompozycja farmaceutyczna
US5859000A (en) 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
US5591736A (en) 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure
US5736537A (en) 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
JPH10508322A (ja) * 1995-10-12 1998-08-18 スーパーゲン，インコーポレイティド ５βステロイドのリポソーム配合物
PT771817E (pt) 1995-10-30 2003-06-30 Oleoyl Estrone Developments S Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso
US5824668A (en) 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
ATE365171T1 (de) * 1995-12-11 2007-07-15 Searle Llc Verfahren zur herstellung einer epoxyverbindung
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US5863910A (en) 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
TW442286B (en) 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
JP2000508643A (ja) * 1996-04-11 2000-07-11 エム． ロリア，ロジャー 腫瘍増殖のインヒビターとしての５―アンドロステン３β，１７αジオール
US5789170A (en) 1996-05-23 1998-08-04 Wisconsin Alumni Research Foundation Specific co-activator for human androgen receptor
GB9612990D0 (en) 1996-06-20 1996-08-21 Stanford Rock Ltd Compositions and methods for the treatment of chronic infections
DE69709752T2 (de) 1996-06-27 2002-07-18 Ligand Pharm Inc Androgen rezeptor modulator verbindungen und verfahren
US5709878A (en) 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US5930728A (en) 1996-08-29 1999-07-27 Ericsson Inc. Up converted home base station
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
US5891865A (en) 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
US5872147A (en) 1996-12-05 1999-02-16 Bio-Technology General Corp. Use of oxandrolone in the treatment of chronic obstructive pulmonary disease
US5945412A (en) 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
WO1998050041A1 (en) 1997-05-06 1998-11-12 Imarx Pharmaceutical Corp. Novel prodrugs comprising fluorinated amphiphiles
WO1998058543A1 (en) 1997-06-20 1998-12-30 Gubarev Michael J Method to enhance innate immunity defense mechanisms by treatment with plant-derived alkaloids
US5859900A (en) * 1997-08-19 1999-01-12 At&T Corp Universal call access with reverse billing
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
ATE293102T1 (de) 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
IL140225A0 (en) * 1998-06-11 2002-02-10 Endorech Inc PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING ANDROST-5-EN-3beta; 17beta;-DIOL OR PRODRUGS THEREOF
WO2000004152A2 (en) 1998-07-17 2000-01-27 University Of Rochester Androgen receptor coactivators
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
WO2000032201A2 (en) * 1998-11-24 2000-06-08 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroids for the treatment of malaria and trypanosomiasis
US20080015174A1 (en) 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
AU775614B2 (en) 1998-11-24 2004-08-05 Harbor Biosciences, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
AU1923500A (en) 1998-11-27 2000-06-19 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis
US6767903B1 (en) 1998-12-23 2004-07-27 Schering Ag New7α, 17α-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases
ATE309205T1 (de) 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
ATE259825T1 (de) 1999-03-23 2004-03-15 Hollis Eden Pharmaceuticals Hemihydrat von 16.alpha.-bromoepiandrosterone
DE19929715A1 (de) 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
WO2001030802A2 (en) 1999-10-25 2001-05-03 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2002028880A2 (en) 2000-10-06 2002-04-11 Aeson Therapeutics Inc. Compounds useful for treating hypertriglyceridemia
US20030232797A1 (en) 2002-06-06 2003-12-18 Forbes Medi-Tech Inc. Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
EP1615944A4 (en) 2003-04-01 2010-08-11 Harbor Biosciences Inc ANTI-ORANGE PROBLEMS WITH MARGINAL AGONIST EFFECT AND METHOD OF USE
WO2006110172A2 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals.Inc. Steroid analogs and characterization and treatment methods
US7910755B2 (en) * 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
US20060073099A1 (en) * 2004-10-01 2006-04-06 Frincke James M Treatment screening methods
JP2008052552A (ja) * 2006-08-25 2008-03-06 Brother Ind Ltd プリンタ制御装置、プログラム、及び記録媒体
US20080221074A1 (en) 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
US8217025B2 (en) 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US20080153792A1 (en) 2006-11-17 2008-06-26 Frincke James M Drug Identification and Treatment Method

Also Published As

Publication number Publication date
AU7736300A (en) 2001-04-30
EP1955700A3 (en) 2008-12-10
DE60045751D1 (de) 2011-04-28
EP1832598A2 (en) 2007-09-12
US7691835B2 (en) 2010-04-06
US8367646B2 (en) 2013-02-05
EP1955700A2 (en) 2008-08-13
EP1832598A3 (en) 2008-01-02
CA2670236A1 (en) 2001-04-05
US8076316B2 (en) 2011-12-13
WO2001023405A2 (en) 2001-04-05
CA2669753A1 (en) 2001-04-05
US20100240633A1 (en) 2010-09-23
US20120071454A1 (en) 2012-03-22
US20080176823A1 (en) 2008-07-24
EP1228083A2 (en) 2002-08-07
CA2670236C (en) 2012-06-05
US7776845B2 (en) 2010-08-17
US7696189B1 (en) 2010-04-13
US7863261B2 (en) 2011-01-04
CA2669753C (en) 2012-06-26
US20080058301A1 (en) 2008-03-06
US20110098260A1 (en) 2011-04-28
DK1955700T3 (da) 2011-05-23
US20080021006A1 (en) 2008-01-24
ATE501722T1 (de) 2011-04-15
WO2001023405A3 (en) 2002-05-30
EP1955700B9 (en) 2011-09-07
EP2322182A1 (en) 2011-05-18
US7906497B2 (en) 2011-03-15
CA2386095A1 (en) 2001-04-05
EP1955700B1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
PT1955700E (pt) Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MXPA01013395A (es) Tratamiento de cancer de prostata con anticuerpos anti-erbb2.
CZ2000531A3 (en) Method of prevention or therapy of estrogen-dependent diseases and disorders
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
HK1022301A1 (en) Conjugates of cisdocosahexaenoic acid and paclitaxel
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
GB9815177D0 (en) Treatment of skin disorders
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
GB9621630D0 (en) Treatment of skin disorders
EP1427418A4 (en) PIPERAZINONE COMPOUNDS AS ANTITUMOR AND ANTICANCER AGENTS AND METHODS OF TREATMENT
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
EP1324761A4 (en) URIDIN TREATMENT FOR PATIENTS WITH HIGH PURINE LEVELS
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
MXPA02001204A (es) Compuestos calciliticos.
ATE333277T1 (de) Behandlung von dyskinesie
IL139303A0 (en) Treatment of arthritis and other similar conditions
HK1086775A1 (en) Uses of fluorinated triazoles for treating affective or attention disorders
HK1082727A1 (en) 2&#34; oxo-voruscharin and derivatives thereof